Related News
20Jul
Charles Large to speak at ‘Fragile X syndrome webinar – in pursuit of a cure’ World Fragile X Day
0 CommentsAutifony CEO Charles Large will be speaking at the webinar ‘Fragile X syndrome – in pursuit of a cure’ World... Read More →
07May
Autifony presents key efficacy data for AUT00206 from a first-in-patient safety/PK study in patients with schizophrenia at the Schizophrenia International Research Society annual meeting
0 CommentsStevenage 16th April – This weekend Dr Charles Large will present key biomarker efficacy data from a first study of... Read More →
04Mar
Autifony Therapeutics, Boehringer Ingelheim to collaborate on novel ion channel target with potential in multiple disease areas related to lysosomal storage disorders
0 CommentsStevenage, UK – 04 March 2021 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
26Aug
Autifony Therapeutics regains rights to clinical stage Kv3 programme
0 CommentsStevenage, UK – 26 August 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
04May
Autifony Therapeutics announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing disorders
0 CommentsStevenage, UK – 04 May 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
Tweets
Autifony CEO Charles Large will be speaking at the a webinar ‘Fragile X syndrome – in pursuit of a cure’ World Frag… https://t.co/DPw8f5LPMN
We are currently recruiting for a Senior Electrophysiologist who will be based in Padova Italy, please apply by sen… https://t.co/QL4GySZbKH
RT @Instinctif_HLS:Great to see this exciting new collaboration between @AutifonyLtd and @Boehringer announced! https://t.co/Cx8LI319if
Comments are closed.